-
Arena’s PAH Therapy Reduces Risk of Patients Dying, Phase 2 Trial Shows
Arena Pharmaceuticals’ ralinepagreduced the risk of pulmonary arterial hypertension patients dying, a Phase 2 clinical trial showed.
Read more about this study here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.